Insider: Klee Justin B. Co-Chief Executive Officer - Amylyx Pharmaceuticals, Inc.
| Company Holdings |
| Direct | Indirect Ownership | Total | |
| Shares | 3,355,276 | 0 | 3,355,276 |
| Value | $48,718,607.52 | $0.00 | $48,718,607.52 |
Trans. Date |
Trans. Type |
Shares |
Ownership Type |
Issue Type |
Price |
Trans. Value |
Total Shares Owned |
|---|---|---|---|---|---|---|---|
| 03/31/2025 | DDS | 21,490 | Direct | COM | $3.46 | $74,454.25 | 3,355,276 |
| 03/03/2025 | DDS | 4,595 | Direct | COM | $3.15 | $14,483.44 | 3,196,648 |
| 02/03/2025 | DDS | 11,855 | Direct | COM | $3.47 | $41,103.66 | 3,164,933 |
| 01/06/2025 | DDS | 7,471 | Direct | COM | $4.04 | $30,201.52 | 3,176,788 |
| 09/30/2024 | DDS | 18,589 | Direct | COM | $3.20 | $59,429.03 | 3,120,569 |
| 03/05/2024 | DDS | 4,135 | Direct | COM | $18.73 | $77,439.87 | 2,959,308 |
| 01/09/2024 | DDS | 5,841 | Direct | COM | $16.33 | $95,372.43 | 2,836,776 |
| 03/16/2023 | DDS | 96,555 | Direct | COM | $31.84 | $3,074,359.48 | 2,796,062 |
| 03/16/2023 | DDS | 3,445 | Direct | COM | $32.48 | $111,876.72 | 2,792,617 |
| 01/06/2023 | AAS | 4,122 | Direct | COM | $36.08 | $148,717.23 | 2,894,463 |
| 01/06/2023 | AAS | 1,846 | Direct | COM | $36.79 | $67,912.12 | 2,892,617 |
| 1 You are at page 1 of 1 pages |
|
Transaction Type Key First letter: A = Acquired, D = Disposed Second letter: A = Grant, award or other acquisition pursuant to Rule 16b-3(d) C = Conversion of derivative security | D = Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | E = Expiration of short derivative position | F = Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3. | G = Gift | H = Expiration (or cancellation) of long derivative position with value received | I = Discretionary transaction in accordance with Rule 16b-3(f) | J = Other | L = Small acquisition under Rule 16a-6 | M = Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | O = Exercise of out-of-the-money derivative security | P = Open market or private purchase | S = Open market or private sale | U = Disposition pursuant to a tender of shares in a change of control transaction | W = Acquisition or disposition by will or the laws of descent and distribution | X = Exercise of in-the-money or at-the-money derivative security | Z = Deposit into or withdrawal from voting trust |
 |
Send to Excel |
© 2000 - 2025 Zacks Investment Research